TwinStrand Biosciences Says Delaware Court Entered Final Judgment Awarding More Than $245.2M Against Guardant Health, Orders 6% Royalty On 11 Products Through Patent Expiration March 15, 2033
Share
Why It Matters
A court decided that Guardant Health has to pay TwinStrand over $245 million and give them a portion of money from 11 products until 2033, because of a patent disagreement. When companies lose big patent cases, it can change how profitable they'll be, so it's worth watching how they adjust their business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.